Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment
Status:
Completed
Trial end date:
2010-06-24
Target enrollment:
Participant gender:
Summary
The purpose of this clinical study is to determine the effectiveness (ability to provide
beneficial treatment of the disease) and safety of pralatrexate compared to erlotinib when
given to non-small cell lung cancer (NSCLC) patients who are current or former cigarette
smokers and who have received at least 1 prior treatment with a platinum drug (cisplatin or
carboplatin)
Phase:
Phase 2
Details
Lead Sponsor:
Spectrum Pharmaceuticals, Inc
Treatments:
10-deazaaminopterin Aminopterin Erlotinib Hydrochloride Folic Acid Hydroxocobalamin Vitamin B 12 Vitamin B Complex Vitamins